Essbio Balance Sheet Health
Financial Health criteria checks 2/6
Essbio has a total shareholder equity of CLP374.4B and total debt of CLP594.6B, which brings its debt-to-equity ratio to 158.8%. Its total assets and total liabilities are CLP1,072.1B and CLP697.8B respectively. Essbio's EBIT is CLP74.9B making its interest coverage ratio 4.6. It has cash and short-term investments of CLP14.3B.
Key information
158.8%
Debt to equity ratio
CL$594.58b
Debt
| Interest coverage ratio | 4.6x |
| Cash | CL$14.33b |
| Equity | CL$374.36b |
| Total liabilities | CL$697.77b |
| Total assets | CL$1.07t |
Recent financial health updates
Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?
May 30
Here's Why Essbio (SNSE:ESSBIO-C) Has A Meaningful Debt Burden
Feb 15Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?
Nov 17Recent updates
Investors Appear Satisfied With Essbio S.A.'s (SNSE:ESSBIO-C) Prospects As Shares Rocket 48%
May 21We Think That There Are More Issues For Essbio (SNSE:ESSBIO-C) Than Just Sluggish Earnings
Sep 15Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?
May 30A Look At The Intrinsic Value Of Essbio S.A. (SNSE:ESSBIO-C)
Mar 29Should You Be Impressed By Essbio's (SNSE:ESSBIO-C) Returns on Capital?
Mar 09Here's Why Essbio (SNSE:ESSBIO-C) Has A Meaningful Debt Burden
Feb 15Should Essbio S.A. (SNSE:ESSBIO-C) Focus On Improving This Fundamental Metric?
Jan 04
Has Essbio (SNSE:ESSBIO-C) Got What It Takes To Become A Multi-Bagger?
Dec 08Is Essbio (SNSE:ESSBIO-C) Using Too Much Debt?
Nov 17Financial Position Analysis
Short Term Liabilities: ESSBIO-C's short term assets (CLP67.9B) exceed its short term liabilities (CLP64.8B).
Long Term Liabilities: ESSBIO-C's short term assets (CLP67.9B) do not cover its long term liabilities (CLP632.9B).
Debt to Equity History and Analysis
Debt Level: ESSBIO-C's net debt to equity ratio (155%) is considered high.
Reducing Debt: ESSBIO-C's debt to equity ratio has increased from 106.8% to 158.8% over the past 5 years.
Debt Coverage: ESSBIO-C's debt is not well covered by operating cash flow (17.2%).
Interest Coverage: ESSBIO-C's interest payments on its debt are well covered by EBIT (4.6x coverage).